AGEN2034 + AGEN1884
Phase 2Withdrawn 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Angiosarcoma
Conditions
Angiosarcoma
Trial Timeline
Feb 1, 2021 → Sep 13, 2021
NCT ID
NCT04607200About AGEN2034 + AGEN1884
AGEN2034 + AGEN1884 is a phase 2 stage product being developed by Agenus for Angiosarcoma. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04607200. Target conditions include Angiosarcoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04607200 | Phase 2 | Withdrawn |
| NCT03894215 | Phase 2 | Active |
Competing Products
6 competing products in Angiosarcoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Eribulin | Eisai | Phase 2 | 52 |
| Avelumab + Paclitaxel | Merck | Phase 2 | 52 |
| Pembrolizumab plus Lenvatinib | Merck | Phase 2 | 52 |
| Pazopanib + Paclitaxel | Novartis | Phase 2 | 52 |
| regorafenib | Bayer | Phase 2 | 49 |
| Vusolimogene Oderparepvec (VO) + Pembrolizumab | Replimune | Phase 2 | 44 |